Westport Asset Management Inc. maintained its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 14,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Westport Asset Management Inc.’s holdings in Gilead Sciences were worth $991,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Windsor Financial Group LLC raised its holdings in Gilead Sciences by 8.6% during the 2nd quarter. Windsor Financial Group LLC now owns 9,769 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 772 shares during the period. Beacon Investment Advisory Services Inc. increased its stake in Gilead Sciences by 2.0% in the second quarter. Beacon Investment Advisory Services Inc. now owns 17,156 shares of the biopharmaceutical company’s stock worth $1,214,000 after purchasing an additional 344 shares during the period. Cornerstone Capital Inc. increased its stake in Gilead Sciences by 7.1% in the second quarter. Cornerstone Capital Inc. now owns 49,166 shares of the biopharmaceutical company’s stock worth $3,480,000 after purchasing an additional 3,260 shares during the period. Aspiriant LLC increased its stake in Gilead Sciences by 32.3% in the second quarter. Aspiriant LLC now owns 3,894 shares of the biopharmaceutical company’s stock worth $276,000 after purchasing an additional 950 shares during the period. Finally, Ballentine Partners LLC increased its stake in Gilead Sciences by 63.4% in the second quarter. Ballentine Partners LLC now owns 8,549 shares of the biopharmaceutical company’s stock worth $630,000 after purchasing an additional 3,318 shares during the period. Institutional investors own 73.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/10/21/westport-asset-management-inc-has-991000-stake-in-gilead-sciences-inc-gild.html.

In related news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last three months, insiders sold 446,819 shares of company stock valued at $36,338,919. Insiders own 1.30% of the company’s stock.

A number of analysts have weighed in on the company. Jefferies Group LLC reiterated a “hold” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 11th. Leerink Swann increased their target price on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday. BMO Capital Markets reiterated a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Friday. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Thursday, July 13th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $85.64.

Gilead Sciences, Inc. (GILD) opened at 81.21 on Friday. The stock has a 50 day moving average price of $82.63 and a 200 day moving average price of $72.65. The stock has a market capitalization of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.08 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post $8.74 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.